Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay حسب Di Han (618795)

الموضوعات:

Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay حسب Di Han (618795)

الموضوعات:

Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay حسب Di Han (618795)

الموضوعات:

Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay حسب Di Han (618795)

الموضوعات:

Noise decrease rate comparison. حسب Xianlin Ren (22783589)

Drug combinations with trametinib decrease the colony-forming ability of GIST cell lines. حسب Anu Gupta (467592)

Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

"…Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis…"

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

"…Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis…"

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

"…Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis…"

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

"…Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis…"

Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

"…Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis…"

Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

"…Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis…"

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

"…Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis…"

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

"…Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis…"

Novel chromobox 2 inhibitory peptide decreases tumor progression حسب Lindsay W. Brubaker (15099942)

Supplementary Figure 3 from Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression حسب Thomas J. Rogers (8041841)

Supplementary Figure 2 from Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression حسب Thomas J. Rogers (8041841)

Supplementary Figure 1 from Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression حسب Thomas J. Rogers (8041841)

Hypoxia Resistance of Sterile Mutants. حسب Cassidy Hemphill (12667290)

"…Data show that germline ablated animals (<i>glp-1(ts)</i> and <i>glp-4(ts)</i>), masculinized <i>fem-3(q20)</i> mutants (<i>fem-3(masculinized)</i>) and <i>gld-1(tumor)</i> mutants are highly resistant to hypoxic injury, whereas the feminized <i>fem-3(e2006)</i> mutant (<i>fem-3(feminized)</i>) displays close to wild type hypoxia sensitivity. …"

Cabozantinib treatment decreases microvessel density and increases hypoxic stress in SCNPC PDX models. حسب Mark P. Labrecque (10011469)